CVS Quit Selling Cigarettes, but It’s Found a Patch for Sales
CVS executives knew that some of their sales would go up in smoke when they decided last year to stop selling cigarettes. The press release announcing that all 7,600 CVS stores nationwide would stop selling all tobacco products acknowledged that sales would take a hit. Still, the company said, “This is the right thing to do.”
The costs of the decision are now becoming clear. CVS Health’s general merchandise sales slumped 7.8 percent last quarter on a same-store basis, the company said Tuesday. The company claims non-pharmacy sales would have stayed the same if tobacco sales — and the other products cigarette buyers added to their baskets — were removed from sales figures for the same quarter in 2014.
Related: Why Smoking Is Even Worse Than We Thought
Same-store sales in the pharmacy category climbed 4.1 percent, boosting overall same-store sales growth to 0.5 percent compared with the second quarter of last year, down from a 1.2 percent year-over-year increase the previous quarter. Net revenue overall grew by 7.4 percent to $37.2 billion, helped by pharmacy services revenue that surged 11.9 percent ($2.6 billion) to $24.4 billion. The company has reportedly increased its market share in the health and beauty categories (it did, however, narrow its full-year earnings forecast).
So even as the move to drop cigarettes has cost the company, its bet on health as the source of future growth may be starting to pay off. CVS stock dropped in the wake of its earnings announcement, but shares are still up more than 15 percent on the year and 44 percent over the past 12 months.
Chart of the Day: Boosting Corporate Tax Revenues
The leading candidates for the Democratic presidential nomination have all proposed increasing taxes on corporations, including raising income tax rates to levels ranging from 25% to 35%, up from the current 21% imposed by the Republican tax cuts in 2017. With Bernie Sanders leading the way at $3.9 trillion, here’s how much revenue the higher proposed corporate taxes, along with additional proposed surtaxes and reduced tax breaks, would generate over a decade, according to calculations by the right-leaning Tax Foundation, highlighted Wednesday by Bloomberg News.
Chart of the Day: Discretionary Spending Droops
The federal government’s total non-defense discretionary spending – which covers everything from education and national parks to veterans’ medical care and low-income housing assistance – equals 3.2% of GDP in 2020, near historic lows going back to 1962, according to an analysis this week from the Center on Budget and Policy Priorities.
Chart of the Week: Trump Adds $4.7 Trillion in Debt
The Committee for a Responsible Federal Budget estimated this week that President Trump has now signed legislation that will add a total of $4.7 trillion to the national debt between 2017 and 2029. Tax cuts and spending increases account for similar portions of the projected increase, though if the individual tax cuts in the 2017 Republican overhaul are extended beyond their current expiration date at the end of 2025, they would add another $1 trillion in debt through 2029.
Chart of the Day: The Long Decline in Interest Rates
Are interest rates destined to move higher, increasing the cost of private and public debt? While many experts believe that higher rates are all but inevitable, historian Paul Schmelzing argues that today’s low-interest environment is consistent with a long-term trend stretching back 600 years.
The chart “shows a clear historical downtrend, with rates falling about 1% every 60 years to near zero today,” says Bloomberg’s Aaron Brown. “Rates do tend to revert to a mean, but that mean seems to be declining.”
Chart of the Day: Drug Price Plans Compared
Lawmakers are considering three separate bills that are intended to reduce the cost of prescription drugs. Here’s an overview of the proposals, from a series of charts produced by the Kaiser Family Foundation this week. An interesting detail highlighted in another chart: 88% of voters – including 92% of Democrats and 85% of Republicans – want to give the government the power to negotiate prices with drug companies.
